Giles Major

Building lifelines: A narrative review and pragmatic implementation framework for developing centralised adult chronic intestinal failure services

Trevor Tabone, Giles Major, Lal Simon

mt, ch, gb (code pays fourni par la source)

Iléostomie à haut débit

Samuel Nyffeler, Giles Major

High-output stoma, which often occurs after ileostomy, results in substantial enteric losses that can lead to dehydration, electrolyte disturbances, and malnutrition. Management requires a multidisciplinary approach including rehydration, tailored nutrition, and therapies aimed at reducing stoma output. First-line management is restoration of …

ch (code pays fourni par la source)

Alternative Gastrointestinal Conditions Identified in Patients Meeting Rome IV Criteria for Irritable Bowel Syndrome or Functional Diarrhea Referred to Secondary Care: A Prospective Study

Dennis Poon, Giles Major, Jervoise N. Andreyev

Introduction: Organic gastrointestinal (GI) disorders can be missed in individuals with irritable bowel syndrome (IBS). This study investigated the frequency of organic disorders in patients with diarrhea-predominant IBS or functional diarrhea and the impact of treatment for any identified alternative diagnoses. Methods: …

gb, ch (code pays fourni par la source)

A focus group study to assess perspectives of patients with irritable bowel syndrome on human milk oligosaccharides and lifestyle insights

Patricia Sanz Morales, Anisha Wijeyesekera, M. Denise Robertson, James E. Kennedy et autres

OBJECTIVE: To explore the impact of Irritable Bowel Syndrome (IBS) on quality of life (QoL) measures, with specific focus on symptoms experienced and their impact upon diet, lifestyle, and mood. Insights into triggers of IBS flare-ups and the potential barriers to the …

gb, ch (code pays fourni par la source)

CF Tummy Tracker: A Cystic Fibrosis–Specific Patient-Reported Outcome Measure for Daily Gastrointestinal Symptom Burden

Rebecca J Calthorpe, Hisham A. Saumtally, Laura Howells, N. Goodchild et autres

Objective: To develop a cystic fibrosis (CF)-specific patient-reported outcome measure (PROM) to measure the daily burden of gastrointestinal symptoms for people with cystic fibrosis (pwCF) aged 12 years and older and address the lack of validated outcome measures for gastrointestinal symptoms in …

gb, ch (code pays fourni par la source)

An in vitro batch culture study to assess the fermentation of human milk oligosaccharides by faecal microbiota from healthy and irritable bowel syndrome stool donors

Patricia Sanz Morales, Anisha Wijeyesekera, M. Denise Robertson, Giles Major et autres

Abstract This study explored the effects of different human milk oligosaccharides (HMOs), solely and in combination, on gut microbiota composition and metabolic activity (organic acid production), using anaerobic in vitro batch culture fermenters. The aim was to compare prebiotic effects of HMOs …

gb, ch, us (code pays fourni par la source)

A longitudinal study assessing the impact of elexacaftor/tezacaftor/ivacaftor on gut transit and function in people with cystic fibrosis using magnetic resonance imaging (MRI)

Alexander Yule, Christabella Ng, A. Flores Recto, Florence Lockwood et autres

BACKGROUND: Gastrointestinal (GI) symptoms in cystic fibrosis (CF) are common and disruptive. The effect of cystic fibrosis transmembrane conductance regulator (CFTR) modulators on the GI tract is not fully understood. The aim was to use magnetic resonance imaging (MRI) to determine if …

gb, de, ch, us (code pays fourni par la source)

The impact of gastroesophageal reflux disease and its treatment on interstitial lung disease outcomes

Alannah Quinlivan, Dennis R. Neuen, Dominique Hansen, Wendy Stevens et autres

BACKGROUND: To determine the relationship between gastroesophageal reflux disease (GORD) and its treatment and interstitial lung disease in patients with systemic sclerosis (SSc). METHODS: SSc patients from the Australian Scleroderma Cohort Study (ASCS) were included. GORD was defined as self-reported GORD symptoms, …

au (code pays fourni par la source)

Impact of extended Elexacaftor/Tezacaftor/Ivacaftor therapy on the gut microbiome in cystic fibrosis

Ryan Marsh, Claudio Dos Santos, Alexander Yule, Neele S. Dellschaft et autres

BACKGROUND: There is a paucity of knowledge on the longer-term effects of CF transmembrane conductance regulator (CFTR) modulator therapies upon the gut microbiome and associated outcomes. In a pilot study, we investigated longitudinal Elexacaftor/Tezacaftor/Ivacaftor (ETI) therapy on the gut microbiota, metabolomic functioning, …

gb, ch (code pays fourni par la source)

A randomised crossover trial of tezacaftor-ivacaftor for gut dysfunction in cystic fibrosis with magnetic resonance imaging (MRI) outcomes: a pilot study.

Christabella Ng, Neele S. Dellschaft, Caroline Louise Hoad, Luca Marciani et autres

Background: People with cystic fibrosis (CF) can experience recurrent chest infections, pancreatic exocrine insufficiency and gastrointestinal symptoms. New cystic fibrosis transmembrane conductance regulator (CFTR) modulator drugs improve lung function but gastrointestinal effects are unclear. We aimed to see if a CFTR modulator …

gb, us, de, ch, br, bd (code pays fourni par la source)

Impact of extended Elexacaftor/Tezacaftor/Ivacaftor therapy on the gut microbiome in cystic fibrosis

Ryan Marsh, Claudio Dos Santos, Alexander Yule, Neele S. Dellschaft et autres

Abstract Background There is a paucity of knowledge on the longer-term effects of CF transmembrane conductance regulator (CFTR) modulator therapies upon the gut microbiome and associated outcomes. In a pilot study, we investigated longitudinal Elexacaftor/Tezacaftor/Ivacaftor (ETI) therapy on the gut microbiota, metabolomic …

gb, ch (code pays fourni par la source)

What Does Healthy Microbiome Development Look Like? State of the Art and Beyond

Giles Major, Shaillay Kumar Dogra, Norbert Sprenger

The community of microorganisms colonizing the gut changes during the first postnatal years of life. This ecosystem, henceforth described as the microbiome, modulates infant physiology and health, but uncertainty remains about the significance of variation in microbiome composition and function. Some may …

gb, ch (code pays fourni par la source)